latest news releases from the newsroom
Composition for KLIPPAN Molndal AB Fixed
KLIPPAN, Sweden, Nov. 4, 2005 (PRIMEZONE) -- At today's negotiation, Molndal District Court fixed the composition for KLIPPAN Molndal AB at 37%, i e in accordance with the composition proposal presented.
Composition For Klippan AB Fixed
KLIPPAN, Sweden, Nov. 04, 2005 (PRIMEZONE) -- At today's negotiation, Helsingborg District Court fixed the composition for KLIPPAN AB at 37%, i.e., in accordance with the composition proposal presented.
Details -- Odfjell's 3Q 2005 Presentation
Bergen, Norway, Nov. 4, 2005 (PRIMEZONE) -- As earlier announced, Odfjell ASA's third quarter 2005 result will be released on Wednesday 16 November 2005. The results will be published on Oslo Boers at www.newsweb.no as well as made available on www.huginonline.com and on www.odfjell.com.
Observer Conducts Previously Announced Directed New Share Issue Comprising of 4 Million Shares
STOCKHOLM, Sweden, Nov. 4, 2005 (PRIMEZONE) -- The Board of Directors of Observer AB (publ) has on November 3, 2005 decided to increase the company's share capital through a directed new share issue of 4 million new shares. The new share issue was announced on November 1. The shares are subscribed for by Carnegie Investment Bank AB for further distribution to a limited number of institutional investors in Sweden and abroad. The decision was based on the authorization which the Board of Directors obtained at the AGM held on April 28, 2005.
Metso Paper's Gaspesia Project into Conclusion
HELSINKI, Finland, Nov. 4, 2005 (PRIMEZONE) -- Metso Paper received in 2002 an order for a rebuild of an extensive printing and writing paper line from Papiers Gaspesia in Chandler, Quebec, Canada. The rebuild was expected to be completed in mid 2004. The project was, however, stopped early 2004 due to problems in financing. Consequently Metso Paper's accounts receivable were written off by EUR 15 million in total. The write down was included in the 2004 financial result.
Enea Sells Remaining own Shares
TABY, Sweden, Nov. 4, 2005 (PRIMEZONE) -- As per November 3, 2005, Enea has sold the remaining 59 880 own shares at an average share price of SEK 4.65 in accordance with a mandate from the Annual General Meeting of May 18, 2005. The shareholding originates from a previous incentive program.
Murray, Frank & Sailer LLP
Investor Notice: Murray, Frank & Sailer LLP Has Filed a Shareholder Class Action Against Barrier Therapeutics, Inc. -- BTRX
NEW YORK, Nov. 3, 2005 (PRIMEZONE) -- Murray, Frank & Sailer LLP has filed a class action lawsuit in the United States District Court for the District of New Jersey on behalf of purchasers of Barrier Therapeutics, Inc. ("Barrier") (Nasdaq:BTRX)(Berlin:BTRX)(Berlin:BXE) common stock during the period between April 29, 2004 and June 29, 2005 (the "Class Period"). Shareholders who purchased Barrier stock in the Initial Public Offering ("IPO") on April 29, 2004 and/or in its Secondary Offering on February 9, 2005 are also included in this class action. Murray, Frank & Sailer LLP is seeking to pursue remedies under the Securities Exchange Act of 1934 and the Securities Act of 1933 against defendants Barrier Therapeutics, Inc., Geert Cauwenbergh, Anne M. Vanlent and Charles T. Nomides.
ViroPharma Announces Additional Investment for Vancocin Supply
EXTON, Pa., Nov. 3, 2005 (PRIMEZONE) -- ViroPharma Incorporated (Nasdaq:VPHM) today announced the amendment of its manufacturing agreement with Eli Lilly and Company (Lilly) (NYSE:LLY) in order to increase Lilly's supply of Vancocin(r) to ViroPharma over and above the supply necessary to meet ViroPharma's expectations for product demand. ViroPharma will pay Lilly an additional amount of up to $4.5 million in addition to the original contract price through early 2006. This investment is representative of ViroPharma's effort to anticipate the potential for increased demand for the product, should the incidence and severity of Clostridium difficile infection continue to increase at a higher than expected rate. Vancocin is indicated for the treatment of antibiotic-associated pseudomembranous colitis caused by C. difficile.